Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03236038
Other study ID # 2017536
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2017
Est. completion date December 31, 2019

Study information

Verified date December 2020
Source Corporacion Parc Tauli
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Exocrine pancreatic insufficiency (EPI) is the inability of the pancreas to perform a normal digestive function. The prevalence of IPE in patients with decompensated hepatic cirrhosis (HC) is unknown and most published series are short, old and use a single diagnostic technique with potential risk of false positives and negatives. Demonstrating IPE in a patient with HC can change their vital prognosis with the indication of pancreatic enzymes that can improve their nutritional status and help control their decompensations. Objectives: To assess the prevalence of IPE in patients with decompensated CH. To establish correlation between fecal elastase and 13C triolein breath test. Methodology: Unicentric, transversal study that will be carried out during hospitalization. Patients with HC who enter for decompensation and requiere hospitalization will be included consecutively. Exclusion criteria will include prior diagnosis of IPE, suspicion of biliary obstruction, more than 5 dep / d induced by laxatives or liquid stools. The diagnosis of IPE will be made with the combination of two techniques (13C triolein breath test and fecal elastase). Demographic, epidemiological data, clinical data as well as anthropometric parameters will be collected. A blood test will also be done to assess nutritional status and associated deficits. A multivariate analysis will be performed to assess the predictive factors of IPE


Description:

Exocrine pancreatic insufficiency (EPI) is defined as the inability of the pancreas to perform a normal digestive function. Habitually, it occurs as a result of a severe reduction in the secretion of pancreatic enzymes, although - less frequently - it may be due to the inability of these enzymes to perform their function. Clinically, it has a very broad spectrum of presentation with abdominal discomforts, malnutrition, chronic diarrhea and, in severe cases, steatorrhea. It must be said, however, that it is not until the disease is very evolved with a pancreatic function very deteriorated (more than 90%) that steatorrhea becomes clinically evident. In addition, the onset of symptoms triggered by the intake of fats makes these patients adapt their diet, often unconsciously, so it is not uncommon to find patients with EPI and constipation. To establish the diagnosis of IPE, different clinical tests are used. There are direct methods or invasive (secretin stimulation test, secretin-cerulein Lundh test) and noninvasive or indirect methods (coefficient of fat absorption, fecal elastase, fecal chymotrypsin activity, the pancreoleuril test, test with paraaminobenzoic acid and marked triolein test) are, in general, more accessible to the usual clinical practice. Regarding etiology, the most frequent cause of EPI is chronic pancreatitis, an entity that is closely linked to chronic alcohol consumption. On the one hand, it should be noted that alcohol is a common etiologic factor to both pathogenesis of pancreatic and liver affections. On the other hand, it is well known that the liver and pancreas have a close relationship with regard to their anatomy and physiology. The pancreatic duct and the coledocus bind to the level of the Vater papilla, so that their contents are mixed. Patients with EPI have severe malnutrition, a factor which increases the morbidity and mortality. Therefore, adequately replacing nutritional deficits by enzyme replacement therapy contributes significantly to decrease the complications, the hospital stays and the mortality. It could increase the quality of life of the patients. In addition, patients suffering from liver cirrhosis have other complications arising from malnutrition, as ascites that could be benefited from the improvement of the nutritional profile by enzyme replacement therapy detected in case of EPI. That is why we believe that our study could contribute to improving patient management with decompensated liver cirrhosis. The objective of the study is to assess the prevalence of exocrine pancreatic insufficiency EPI in patients with decompensated alcoholic liver cirrhosis. This is an epidemiological, unicentral, cross-sectional study that will be carried out within the hospital setting from October '17 to October'19. Patients diagnosed with liver cirrrhosis and enter the hepatology unit for clinical decompensation (sd hepatorenal, ascitic decompensation, hepatic encephalopathy, gastrointestinal bleeding stable) will be included . The investigators will collect demographic, epidemiology, analytic and clinical data. Anthropometric parameters such as tricipital fold, weight and size, will also be measured, which will allow the calculation of body mass index (BMI). In order to diagnose the presence of IPE, the breath test with triolein marked with 13C (Pancreo-Kit®) will be performed. The study consists of a delay of 8 hours (overnight) and later obtaining a basal sample through exhalation of air in a tube. Subsequently, a substrate (foods with marked triolein) will be administered to the patient and after 30 minutes, it will have to exhale air in a tube every 30 minutes for a total of 6 hours, thus obtaining a total of 13 samples. Blood tests will also be performed on all patients to assess their nutritional status (Hg, albumin, prealbumin, total proteins, cholesterol (HDL / LDL), bilirubin, prothrombin time, triglycerides, liposoluble Vitamins A, D, E and K; Vitamins B1, B12; calcium, phosphorus and magnesium), Hb glucose and collect a sample of solid stool isolated for the determination of the fecal elastase.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date December 31, 2019
Est. primary completion date October 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Patients with histological diagnosis of CH or by clinical, analytical, ecographic or fibroscan criteria. 2. Patients with decompensated HC (ascites, hepatic hydrothorax, hepatorenal syndrome, digestive bleeding due to portal hypertension or hepatic encephalopathy. 3. Signature of informed consent 4. Prevision of hospital admission for a minimum of 48 hours (for the correct completion of the marked triolein test and the collection of samples for fecal elastase) 5. Age between 18 and 85 years. Exclusion Criteria: 1. Previous diagnosis of EPI 2. Suspected biliary tract obstruction 3. Need for high doses of laxative which makes it impossible to collect faecal samples correctly (> 5 dep / d secondary to laxatives) 4. Patients who, due to their clinical situation, are unable to collaborate in the labeled triolein breath test 5. Patients with inability to use the oral route.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Labeled triolein urea breath test
The diagnosis of EPI will be made through the combination of two diagnostic tests. The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma. The fecal elastase test will be performed at our own center (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.) In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed.

Locations

Country Name City State
Spain Parc Tauli Hospital Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Corporacion Parc Tauli

Country where clinical trial is conducted

Spain, 

References & Publications (1)

Aoufi Rabih S, García Agudo R, Legaz Huidobro ML, Ynfante Ferrús M, González Carro P, Pérez Roldán F, Ruiz Carrillo F, Tenías Burillo JM. Exocrine pancreatic insufficiency and chronic pancreatitis in chronic alcoholic liver disease: coincidence or shared — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of exocrine pancreatic insufficiency in decompensated alcoholic cirrhosis The diagnosis of EPI will be made through the combination of two diagnostic tests.
The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma.
Reference value: Normal: > 29%; Pathological: < 29% of the fat administered
The fecal elastase test (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.)
A normal result will be considered: 200 to > 500 µg / g
Slight exocrine pancreatic insufficiency- Moderate: 100 - 200 µg / g
Severe exocrine pancreatic insufficiency: <100 µg / g
In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed.
Coefficient of fat absorption; Pathological if elimination > 7g of fat / day with a diet of 100g fat / day.
This is a prevalence study. Outcome measure will be assessed during patient admision in the hospital. Data will be reported once the inclusion has been completed (2 years).
See also
  Status Clinical Trial Phase
Completed NCT02823964 - EASY: Extended Access to Sollpura Over Years Phase 4
Completed NCT02563080 - Pancreatic Exocrine Insufficiency in Acute Pancreatitis
Completed NCT01427725 - Special Investigation of LipaCreon on Long-term Use in Patients With Pancreatic Exocrine Insufficiency
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Completed NCT05082051 - Oral CDX-7108 in Healthy Adults and EPI Subjects Phase 1
Completed NCT03407534 - Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating
Completed NCT02598128 - Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb) N/A
Completed NCT00559364 - Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea Phase 3
Completed NCT00408317 - Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) Phase 3
Recruiting NCT04548778 - BÜHLMANN fPELA in the Diagnosis of Exocrine Pancreatic Insufficiency
Completed NCT00449878 - Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency Phase 3
Completed NCT00981214 - Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Phase 3
Completed NCT00297167 - Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency Phase 3
Recruiting NCT05480241 - Exocrine Pancreatic Insufficiency After Acute Pancreatitis and Pancreatic Enzyme Replacement Therapy N/A
Recruiting NCT05261997 - Endotherapy for Painless Chronic Pancreatitis N/A
Completed NCT02370537 - A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI Phase 2
Completed NCT00559052 - An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI) Phase 2
Recruiting NCT04112836 - Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
Completed NCT06278272 - AI Evaluation of Pancreatic Exocrine Insufficiency in CP Patients
Completed NCT02734810 - SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis Phase 3